Shares of AngioDynamics, Inc. (NASDAQ:ANGO) have received an average rating of “Hold” from the six brokerages that are covering the firm, Market Beat.com reports. Four investment analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $16.50.
AngioDynamics (NASDAQ:ANGO) opened at 11.351 on Monday. The stock’s 50 day moving average price is $12.09 and its 200 day moving average price is $13.95. The company’s market capitalization is $411.81 million. AngioDynamics has a 12 month low of $11.14 and a 12 month high of $19.80.
AngioDynamics (NASDAQ:ANGO) last released its earnings results on Thursday, October 8th. The company reported $0.11 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.11. The company had revenue of $83.70 million for the quarter. The business’s quarterly revenue was down 4.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.16 EPS. Equities research analysts anticipate that AngioDynamics will post $0.62 earnings per share for the current fiscal year.
ANGO has been the topic of several analyst reports. Zacks Investment Research upgraded AngioDynamics from a “sell” rating to a “hold” rating in a research report on Monday, September 7th. Sidoti initiated coverage on AngioDynamics in a research report on Wednesday, September 23rd. They set a “neutral” rating and a $14.50 target price on the stock. Canaccord Genuity reiterated a “buy” rating and set a $17.50 target price (down from $19.00) on shares of AngioDynamics in a research report on Friday, October 9th. Raymond James lowered their target price on AngioDynamics from $18.00 to $15.00 and set an “outperform” rating on the stock in a research report on Friday, October 9th. Finally, Piper Jaffray reiterated a “hold” rating and set a $14.00 target price (down from $18.00) on shares of AngioDynamics in a research report on Friday, October 9th.
AngioDynamics, Inc. designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease, and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures. The Company offers products within three product groupings: Peripheral Vascular, Vascular Access and Oncology/Surgery. The Company’s Peripheral Vascular products include fluid management, venous, thrombus management, as well as other core products. The Company’s BioFlo products incorporate Endexo technology into the manufacturing and design of its Vascular Access products. Its Oncology/Surgery product offerings include its microwave ablation products, its radiofrequency ablation (NASDAQ:ANGO) and its NanoKnife product lines.